Basel Medical Group Ltd income statement

In fiscal 2026, Basel Medical Group Ltd reported revenue of $12.8m, up 49.9% on the year before and net income of −$582,757, or −$0.61 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Basel Medical Group Ltd: income statement, annual
Fiscal year	2024Jun 2024	2025Jun 2025	2026Jun 2026
Revenue	7	9	13
Interest expense	0	0	0
Income before tax	2	−8	−1
Income tax	0	−0	0
Net income	2	−8	−1
Diluted EPS	$0.10	−$0.43	−$0.61
Diluted shares (average)	16m	19m	2m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BMGL vs NIVF BMGL vs CCM BMGL vs SNDA

More: Health Care Facilities stocks compared, Health Care sector, rankings of US companies

Figures from Basel Medical Group Ltd's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Basel Medical Group Ltd.